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Abstract
Cocaine addiction involves a number of medical, psychological and social problems. Understanding
the genetic aetiology of this disorder will be essential for design of effective treatments. Dopamine-
beta hydroxylase (DbH) catalyzes the conversion of dopamine to norepinephrine and could,
therefore, have an influence on both cocaine action and the basal sensitivity of neurotransmitter
systems to cocaine. Recently, the -1021C>T polymorphism have been found to strongly correlated
with individual variation in plasma DbH activity. To test the influence of this polymorphism on the
susceptibility of cocaine addiction, we decided to genotype it in a sample of 689 cocaine addicts and
832 healthy individuals. Genotypic and allelic analyses did not show any evidence of association with
cocaine addiction, even after correcting for the effect of population stratification and other possible
confounders. Our results do not support a major role of the -1021C>T polymorphism or the gene
itself in the development of cocaine addiction but further examination of other variants within this
gene will be necessary to completely rule out an effect.
Findings
Cocaine is one of the most powerfully addictive of the
drugs of abuse. The number of cocaine users is estimated
at some 13 million worldwide [1]. From those, 15–16%
will become addicted within 10 years of first cocaine use
[2]. Twin and family studies have demonstrated that
cocaine addiction has a strong genetic component but the
exact basis of the heritable factors that have a significant
contribution to this phenotype remain unclear [3].
Cocaine's potent actions in blocking the uptake by neuro-
nal plasma membrane transporters for dopamine (DAT),
serotonin (SERT), and norepinephrine (NET) are well
known [4]. Studies in transgenic mice indicate that both
DAT and SERT can mediate cocaine's rewarding effects,
but the DAT may play the more important role [5]. On the
other hand, mice lacking norepinephrine transporter
demonstrated prolonged clearance of NE, elevated extra-
cellular levels of this catecholamine and were behaviour-
ally hypersensitive to cocaine and amphetamine, as
measured by locomotor stimulation and conditioned
place preference [6]. Similarly, double knockouts of both
SERT and NET showed dramatically enhanced cocaine
place preference [7].
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Dopamine-beta hydroxylase (DbH) catalyzes the conver-
sion of dopamine to norepinephrine (NE) and could,
therefore, have an influence on both cocaine action and
the basal sensitivity of neurotransmitter systems to
cocaine [8]. It has been demonstrated that DbH knockout
mice are hypersensitive to the psychomotor, rewarding,
and aversive effects of cocaine, as measured by locomotor
activity and conditioned place preference [9]. Pharmaco-
logical treatment studies with the DbH inhibitor
disulfiram also indicate that this medication has efficacy
as a treatment for cocaine dependence [10,11].
DbH plasma activity levels are reported to vary widely
among individuals [12]. Several studies have attempted to
find genetic polymorphisms related to differences in
enzyme levels. [13-15]. Cubells and colleagues found that
a 19 base pair insertion/deletion polymorphism and the
SNP 444A>G were associated with plasma DbH levels and
that alleles of similar association to enzymatic levels were
in significant positive disequilibrium. Additionally, the
haplotype containing the two low DbH activity alleles was
also associated with cocaine-induced paranoia [15].
More recently, using extreme phenotypes in samples from
African and European American and Japanese popula-
tions, Zabetian and co-workers [16] reported that the -
1021C>T polymorphism (rs1611115) located in the 5'
flanking region of the gene accounted for between 35–
52% of the variation in plasma DbH activity in these pop-
ulations. More strikingly, individuals with CC genotype
had on average eleven times the enzyme activity of indi-
viduals carrying TT genotype [16]. Most recently, a study
has shown that cocaine users homozygous for the T allele
have an increased propensity to paranoia over time during
cocaine self-administration [17].
However, no study has specifically tested the role of this
variation in cocaine addiction aetiology, where it may be
expected that individuals with the CC genotype might be
more resistant to cocaine's effects. To verify the influence
of this polymorphism on the susceptibility to cocaine
addiction, we decided to conduct an association study in
our previously described sample [18,19] of 689 cocaine
addicts and 832 healthy individuals, from Sao Paulo, Bra-
zil.
The genotyping of the -1021C>T polymorphism was per-
formed under contract by K-Biosciences (Cambridge, UK)
blind to status using an amplifluor assay. Hardy-Weinberg
equilibrium, genotype and allele frequencies were com-
pared using a χ2 test and odds ratios and 95% confidence
intervals were derived from logistic regression, using SPSS
v12.0. We selected a total of 71 (64 SNPs and 7 microsat-
ellites) ancestry-informative markers, e.g. markers that
exhibit large allele frequency differences among the three
main Brazilian ancestral populations (Europeans, Afri-
cans and Native American) to correct for potential popu-
lation stratification in the sample, using the program
ADMIXMAP [20]. The list of markers can be obtained
upon request.
The genotype frequencies were in Hardy-Weinberg equi-
librium in both, case and control groups for the -1021C>T
polymorphism. The genotyping failure rate was around
3%. Genotype counts and frequencies of the polymor-
phism in both groups, as well as allele wise odds ratios
analyses, can be found in Table 1. Genotypic and allelic
distribution did not provide any evidence for association
between the marker and cocaine addiction (χ2 = 1.01; df =
2; p = 0.59 and χ2 = 0.83; df = 1; p = 0.91; OR = 1.08;
95%CI = 0.91–1.28). The correction for population strat-
ification performed by ADMIXMAP did not affect the
allelic association test (z = -0.626; two-tailed p value =
0.53). Further genotypic analyses, dividing the sample by
sex, did not provide evidence of association for males (χ2
= 0.83; df = 2; p = 0.66) and females (χ2 = 0.19; df = 2; p
= 0.91).
Finally, evaluation of different models considering a dom-
inant and a recessive effect for the low activity allele (T)
also did not show difference between cases and controls,
after correction for the potential confounding variables
sex, age and education (OR = 0.91; 95%CI = 0.72–1.15; p
> 0.05) and (OR = 1.07; 95%CI = 0.66–1.74; p > 0.05).
The neurotransmitter norepinephrine and the norepine-
phrine transporter play an important role in the reward-
ing effects of cocaine [6,7], suggesting that genetic
variation in the genes involved in the noradrenergic trans-
mission could be responsible for differences in the indi-
vidual response to cocaine. The DbH gene was an
Table 1: Genotype and allele counts and frequencies (%) of the -1021C>T polymorphism (rs1611115) in the DbH gene among healthy 
controls and cocaine addicts.
Genotype-Wise Allele-Wise
CC CT TT Total pvalue C T pvalue OR (95%IC)
Controls 487 59% 294 35% 51 6% 832 0.59 1268 76% 396 24% 0.35 1.08(0.9–1.28)
Cases 421 61% 228 33% 40 6% 689 1070 78% 308 22%Behavioral and Brain Functions 2008, 4:1 http://www.behavioralandbrainfunctions.com/content/4/1/1
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interesting candidate to test this hypothesis since it
encodes for the enzyme responsible for the production of
NE and consequently for the control of the NE/DA ratio
in noradrenergic neurons. The strong association reported
between -1021C>T genotypes and DbH levels, robustly
indicated that this, or another polymorphism in very tight
LD, might be controlling the variation in enzymatic levels
and NE synthesis observed across individuals [8] and
could, therefore, account for increased susceptibility to
abuse cocaine.
However, genotypic and allelic distribution, as well as the
evaluation of recessive or dominant models for the low
activity variant in a Brazilian sample of 689 cocaine
addicts and 832 healthy controls did not provide evidence
of association between this variant and the trait under
study, even after correction for sex age, education and
population stratification.
This is the first study examining the effect of polymor-
phisms in the DbH gene and the susceptibility to cocaine
addiction utilizing a case-control approach. Cubells and
co-workers (2000) [15] have studied cocaine dependent
subjects and demonstrated an association with the low
activity alleles of the insertion/deletion polymorphism
and the SNP 444A>G, but with the development of
cocaine induced paranoia. The results of our study corrob-
orate with the findings by Köhnke et al. (2002) [21] and
Cubells (2002) [22]. Both groups demonstrated that
plasma DbH activity was significantly lower in alcoholic
subjects and in individuals with unipolar major depres-
sion with psychotic features, respectively. However, these
positive associations were independent of genotype at -
1021C>T, e.g. genotypic and allelic distribution for this
polymorphism did not significantly differ between the
groups under study. More recent studies also failed to find
an association between this polymorphism and epilepsy
[23], schizophrenia [24] and Tourette Syndrome [25].
In summary, our results do not support a specific role for
the -1021C>T in cocaine addiction in the Brazilian popu-
lation or a major role for variation in enzymatic activity of
DbH. However, our study does not exclude a minor role
for the DbH protein or its related pathway in the develop-
ment of cocaine addiction and suggests that the examina-
tion of other variants within this gene not in close LD with
the -1021C>T is necessary to completely rule out an effect.
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